In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 4, 1996, Pages 346-351

  Ries, M ^a   Klinge, J ^a   Rauch, R ^a   Trusen, B ^a   Zenker, M ^a   Keuper, H ^b   Harms, D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Behringwerke AG   (Germany)

Author keywords

Alpha 2 antiplasmin; Fibrinolysis; Newborns; Plasminogen; Thrombolytic therapy

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; FIBRINOLYTIC AGENT; PLASMINOGEN; STREPTOKINASE; UROKINASE;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; NEWBORN; PRIORITY JOURNAL; THROMBOSIS;

ADULT; ANTIPLASMIN; CHLORAMINES; FIBRINOLYSIS; HUMANS; INFANT, NEWBORN; OXIDATION-REDUCTION; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; TOSYL COMPOUNDS;

EID: 0029911411     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199611000-00003     Document Type: Article

References (40)

1. Ambrus CM, Ambrus JL, Choi TS, Jung O, Mirand EA, Bartfay-Szabo A. The fibrinolysin system and its relationship to disease in the newborn. Am J Pediatr Hematol Oncol 1979;1:251-60.
2. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
3. Corrigan JJ. Neonatal thrombosis and the thrombolytic system: pathophysiology and therapy. Am J Pediatr Hematol Oncol 1988;10:83-91.
4. Corrigan JJ, Sleeth JJ, Jeter MA, Lox CD. Newborn's fibrinolytic mechanism: components and plasmin generation. Am J Hematol 1989;32:273-8.
5. Ekelund H, Hedner U, Nilsson IM. Fibrinolysis in newborns. Acta Paediatr Scand 1970;59:33-43
6. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95-104.
7. Saleh AA, Hirokawa S, Stowers MA, et al. Effect of mode of delivery on certain parameters of neonatal hemostasis. Thromb Haemost 1993;69:1020.
8. Suarez CR, Walenga J, Mangogna LC, Fareed J. Neonatal and maternal fibrinolysis: activation at time of birth. Am J Hematol 1985;19:365-72.
9. Estelles A, Aznar J, Gilabert J, Parrilla JJ. Dysfunctional plasminogen in full-term newborn. Pediatr Res 1980;14:1180-5.
10. Benavent A, Estellés A, Aznar J, Martinez-Sales V, Gilabert J, Fornas E. Dysfunctional plasminogen in full-term newborn - study of active site of plasmin. Thromb Haemost 1984;51:67-70.
11. Edelberg JM, Enghild JJ, Pizzo SV, Gonzales-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990;86:106-12.
12. Ries M, Zenker M, Klinge J, Keuper H, Harms D. Age related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro. J Pediatr Hematol Oncol 1995;17:260-4.
13. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992;68:325-30.
14. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-7.
15. Barnard DR, Simmons MA, Hathaway WE. Coagulation studies in extremely premature infants. Pediatr Res 1979;13:1330-5.
16. Forestier F, Daffos F. Galactéros F, Bardakijan J, Rainaut M, Benzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986;20:342-6.
17. Holmberg L, Henriksson P, Ekelund H, Astedt B. Coagulation in the human fetus, comparison with term newborn infants. J Pediatr 1974;85:860-4.
18. Jensen AH, Josso F, Zamet P, Monset-Couchard M, Minkowski A. Evolution of blood clotting factor levels in premature infants during the first 10 days of life: a study of 96 cases with comparison between clinical status and blood clotting factor levels. Pediatr Res 1973;7:638-44.
19. Künzer W. Fetales Fibrinogen. Klin Wochenschr 1961;39:536-42.
20. Witt I, Müller H, Künzer W. Evidence for the existence of foetal fibrinogen. Thromb Diath Hemorrh 1969;22:101-9.
21. Schettini F, de Mattia D, Mautone A. Preprothrombin and prothrombin in full-term newborns. Haemostasis 1972;1:271-8.
22. Ekelund H. Fibrinolysis in the first year of life. Acta Paediatr Scand 1972;61:5-10.
23. Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993;69:141-6.
24. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984;10:24-41.
25. Harpel PC, Mosesson MW. Degradation of human fibrinogen by plasma alpha 2-macroglobulin-enzyme complexes. J Clin Invest 1973;52:2175-9.
26. Stief TW, Aab A, Heimburger N. Oxidative inactivation of purified human alpha 2-antiplasmin, antithrombin III, and C1-inhibitor. Thromb Res 1988;49:581-9.
27. Ling X, Delorme M, Berry L, et al. Alpha 2-macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces. Pediatr Res 1995;37:373-8.
28. Ekelund H, Finnström O. Fibrinolysis in pre-term infants and in infants small for gestational age. Acta Paediatr Scand 1972;61:185-96.
29. Ekelund H, Hedner U, Astedt B. Fibrinolysis in human foetuses. Acta Paediatr Scand 1970;59:369-76.
30. Phillips LL, Skrodelis V. A comparison of the fibrinolytic enzyme system in maternal and umbilical-cord blood. Pediatrics 1958;22: 715-26.
31. Ahluwalia JS, Kelsall AWR, Diederich S, Rennie JM. Successful treatment of aortic thrombosis after umbilical catheterization with tissue plasminogen activator. Acta Paediatr 1994;83:1215-7.
32. Anderson BJ, Keeley SR, Johnson ND. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator. Anaesth Intensive Care 1991;19:22-7.
33. Kennedy LA, Drummond WH, Knight ME, Millsaps MM, Williams JL. Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator. J Pediatr 1990;116:798-801.
34. Guérin V, Boisseau MR, Fayon M. Efficiency of Alteplase in the treatment of venous and arterial thrombosis in neonates. Am J Hematoi 1993;42:236-7.
35. Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991;118:467-72.
36. Doyle E, Britto J, Freeman J, Munro F, Motion NS. Thrombolysis with low dose tissue plasminogen activator. Arch Dis Child 1992;67:1483-4.
37. Dillon PW, Fox PS, Berg CJ, Cardella JF, Krummel TM. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. J Pediatr Surg 1993;28:1264-9.
38. Nowak-Göttl U, Schwabe D, Schneider W, Schlösser R, Kreuz W. Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy. Lancet 1992;340: 1105.
39. Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su CA, Kluft C. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung 1988;38:418-22.
40. Tanswell P, Seifried E, Su CA, Feuerer W, Rijken DC. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 1989;46:155-62.